DVAX (Dynavax Pharma) Earnings per share for the last twelve months

Automation of biological product production lines reduces personnel costs, as clearly demonstrated by the YoY TTM earnings per share trend for Dynavax Technologies (DVAX). The value of -310.10 determines the current status of the parameter. Dynavax Technologies (DVAX) revenues are based on the sale of the Heplisav-B vaccine through pharmacies and clinics. Meanwhile, patent protection and strict FDA regulations create a robust barrier for competitors, despite the risks associated with a narrow portfolio.
Financial and market metric breakdowns for Dynavax Technologies Corp (DVAX)

This indicator measures the trailing twelve-month (TTM) net income per share relative to the same period last year, eliminating the time lag associated with quarterly reporting. By analyzing the annual EPS growth rate over the last 12 months, investors assess the financial stability of Dynavax Technologies (DVAX), whose dominance in the hepatitis B vaccine segment confirms the business's ability to act as a stable cash generator.